Sutro Biopharma, Inc.
STRO
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer targetā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$11.93
Price+1.53%
$0.18
1Y
Price
Market Cap
$101.564m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-459.6%
EBITDA Margin-586.6%
Net Profit Margin-396.6%
Free Cash Flow Margin-459.6%
EBITDA Margin-586.6%
Net Profit Margin-396.6%
Free Cash Flow MarginRevenue
$105.646m
+70.3%
1y CAGR+45.8%
3y CAGR+36.8%
5y CAGREarnings
-$216.767m
+4.7%
1y CAGR-32.6%
3y CAGR-27.7%
5y CAGREPS
-$26.00
+12.2%
1y CAGR-10.0%
3y CAGR-8.1%
5y CAGRBook Value
-$87.268m
$209.658m
Assets$296.926m
Liabilities$17.661m
DebtDebt to Assets
8.4%
-0.1x
Debt to EBITDAFree Cash Flow
-$225.113m
-15.7%
1y CAGR-891.3%
3y CAGR-644.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company